ArticleThyroid : official journal of the American Thyroid Association2013

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Frauke Bentzien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.